Elisheva Lew
Sanofi (France)(FR)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Health Systems, Economic Evaluations, Quality of Life, Medication Adherence and Compliance, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes(2019)100 cited
- → Improvement of the uric acid determination by the carbonate method for serum and urine(1961)48 cited
- → Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin(2018)22 cited
- → Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial(2022)18 cited
- → Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy(2021)14 cited
- → Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database(2017)14 cited
- → Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study(2023)14 cited
- → Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK(2021)13 cited
- → iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study(2023)12 cited
- → The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model(2019)12 cited